retatrutide ly3437943 parkinson's disease clinical trial A Study of (LY3437943) in Participants With Obesity and Cardiovascular (TRIUMPH-3) 🔬 Retatrutide — why cardiology

In many cases, pricing may vary as dosage increases during treatment progression

GLP-1R agonists were developed as long-acting therapeutic agents to overcome the short half-life of endogenous GLP-1, namely Semaglutide (Ozempic, Wegovy, Rybelsus)

From the studies and trials we have, Reta is producing very promising results with significant weight loss and no significant side effects

Liu J, Wang H, Huang C

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing pronounced effects on weight and blood glucose

Speaking to a Healthcare Professional About Your Options Speak to your GP before considering retatrutide